Valuation dashboard for United Therapeutics Corporation (UTHR) with P/E 20.87, P/B 3.95, EV/EBITDA 14.11 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets.
Analysis Summary
United Therapeutics Corporation reported revenue of $3.18B in the most recent fiscal year, growing at a 5-year CAGR of 16.5%. Net income reached $1.33B, with a 21.0% 5-year CAGR.
Trailing-twelve-month margins: gross margin 86.1%, operating margin 44.5%, net margin 41.6%.
At $582.47 (closing price, October 29, 2026), UTHR trades at a P/E of 20.87 and an ROE of 20.18%. Market capitalisation stands at $25.0B, placing it among large-cap names.
Balance sheet quality for UTHR: current ratio of 6.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 20.87 |
| Price / Book | 3.95 |
| EV / EBITDA | 14.11 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $727.26 |
| vs Current Price | +24.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| UTHR | United Therapeutics Corporation | $25.0B | 20.87 | 3.95 | 20.2% |
| INSM | Insmed Incorporated | $24.4B | 27.83 | -111.3% | |
| LQDA | Liquidia Corporation | $3.7B | 30.44 | 20.50 | 149.6% |
| TVTX | Travere Therapeutics, Inc. | $4.7B | 192.78 | -55.8% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $136.9B | 31.43 | 6.64 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| MRNA | Moderna, Inc. | $88.9B | 12.54 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $582.47 (closing price, October 29, 2026) |
| Market Cap | $25.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 20.18% |
| Return on Invested Capital | 17.69% |
| Return on Assets | 18.16% |
| Gross Margin | 86.14% |
| Operating Margin | 44.49% |
| Net Margin | 41.56% |
Related companies: INSM · LQDA · TVTX · VRTX · 0QZU.L · MRNA · 0R2M.L · REGN
Explore sector: Healthcare · Biotechnology
More sections of UTHR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks